Search Results

You are looking at 51 - 60 of 2,540 items for :

  • Refine by Access: All x
Clear All
Full access

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

currently accepted framework for quality measurement in oncology, in part based on the structure, process, and outcome model for assessment of healthcare quality defined in the 1960s by Avedis Donabedian. 2 Shortly thereafter, the National Quality Forum

Full access

Ashish Rai, Xuesong Han, Zhiyuan Zheng, K. Robin Yabroff, and Ahmedin Jemal

) mandated the adjustment of Medicare payment rates in response to value-based performance scores—a substantive portion of which is measured using patients' assessment of communication with healthcare providers. 2 The Patient-Centered Outcomes Research

Full access

Grace L. Smith, Maria A. Lopez-Olivo, Pragati G. Advani, Matthew S. Ning, Yimin Geng, Sharon H. Giordano, and Robert J. Volk

and intervention in vulnerable patients, 18 a comprehensive synthesis of the risk factors for and outcomes of financial burdens is needed. We therefore conducted a systematic review of these risk factors and outcomes across studies of US patients with

Full access

Linda Watson, Siwei Qi, Andrea DeIure, Eclair Photitai, Lindsi Chmielewski, and Louise Smith

lower functioning and quality of life. 2 , 5 , 6 Therefore, it is critical to identify patients experiencing severe symptom complexity so that timely, targeted symptom management can be delivered. With research showing benefits of gathering outcome data

Full access

Brad Zebrack and Melissa Butler

recent study of AYA patients with cancer found that engaging with music (listening, performing, rehearsing, practicing, composing, dancing, and imagery) resulted in adaptive outcomes, including the promotion of identity formation and a perceived sense of

Full access

Kah Poh Loh, Maya Abdallah, Meng-Shiou Shieh, Mihaela S. Stefan, Penelope S. Pekow, Peter K. Lindenauer, Supriya G. Mohile, Dilip Babu, and Tara Lagu

prognoses of patients with advanced cancer admitted to the hospital. In this study of hospitalized patients with metastatic cancer who received CCTs, we investigated IPC use and described outcomes (including in-hospital mortality, LOS, discharge

Full access

Jesse D. Troy, Carlos M. de Castro, Mary Ruth Pupa, Greg P. Samsa, Amy P. Abernethy, and Thomas W. LeBlanc

distress has been associated with reduced survival in some cancers. 4 – 6 Myelodysplastic syndromes (MDS) are diagnosed primarily in older people and represent a diverse group of malignant bone marrow disorders with variable clinical outcome. 7 QOL is

Full access

Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt

using SPSS Statistics, version 25 (IBM Corp) and data analyses were performed with STATA, version 14.2 (StataCorp, LP). Explanatory and Outcome Measures The main explanatory variable was the therapy received. The outcome measure was the patients

Full access

Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt

using SPSS Statistics, version 25 (IBM Corp) and data analyses were performed with STATA, version 14.2 (StataCorp, LP). Explanatory and Outcome Measures The main explanatory variable was the therapy received. The outcome measure was the patients

Full access

Marissa B. Lawson, Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone, Scott D. Ramsey, and Janie M. Lee

breast cancers that can be treated with curative intent. 3 – 6 Many socioeconomic factors influence whether women participate in screening mammography and have the associated improved outcomes. 7 Lack of insurance coverage has been established as an